José María
Prieto González
Complexo Hospitalario Universitario de Santiago
Santiago de Compostela, EspañaPublicacións en colaboración con investigadores/as de Complexo Hospitalario Universitario de Santiago (51)
2024
-
Explainable machine learning on baseline MRI predicts multiple sclerosis trajectory descriptors
PLoS ONE, Vol. 19, Núm. 7 JULY
-
Plasma IGFBP-3 and IGFBP-5 levels are decreased during acute manic episodes in bipolar disorder patients
Frontiers in Pharmacology, Vol. 15
2023
-
Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study
Neurology and Therapy, Vol. 12, Núm. 6, pp. 2177-2193
-
Genomic Factors and Therapeutic Approaches in HIV-Associated Neurocognitive Disorders: A Comprehensive Review
International journal of molecular sciences, Vol. 24, Núm. 18
-
MiRNA Differences Related to Treatment-Resistant Schizophrenia
International Journal of Molecular Sciences, Vol. 24, Núm. 3
-
Protein Plasma Levels of the IGF Signalling System Are Altered in Major Depressive Disorder
International Journal of Molecular Sciences, Vol. 24, Núm. 20
-
Results of a focused cardiac ultrasound program conducted by neurologists within a stroke care network with cardiac imaging units
Revista Espanola de Cardiologia, Vol. 76, Núm. 2, pp. 103-111
2022
-
Consensus on early detection of disease progression in patients with multiple sclerosis
Frontiers in Neurology, Vol. 13
-
Consensus statement on the use of alemtuzumab in daily clinical practice in Spain
Neurologia, Vol. 37, Núm. 8, pp. 615-630
-
Expert-Agreed Practical Recommendations on the Use of Cladribine
Neurology and Therapy
2021
-
Evolution of the use of corticosteroids for the treatment of hospitalised COVID-19 patients in Spain between March and November 2020: SEMI-COVID national registry
Journal of Clinical Medicine, Vol. 10, Núm. 19
-
Integrated Management of Multiple Sclerosis Spasticity and Associated Symptoms Using the Spasticity-Plus Syndrome Concept: Results of a Structured Specialists' Discussion Using the Workmat® Methodology
Frontiers in Neurology, Vol. 12
-
Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the “no evidence of disease activity” parameter
Neurologia, Vol. 36, Núm. 5, pp. 346-352
-
Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement
Neurologia, Vol. 36, Núm. 1, pp. 50-60
-
Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years” accumulated evidence from clinical trials
Expert Review of Neurotherapeutics, Vol. 21, Núm. 7, pp. 755-778
-
Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports
Expert Review of Neurotherapeutics, Vol. 21, Núm. 5, pp. 547-558
-
Temporal trends in the incidence and prevalence of Multiple Sclerosis in the Northwest of Spain
Multiple Sclerosis and Related Disorders, Vol. 52
-
XIII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2020 (I)
Revista de neurologia, Vol. 72, Núm. 11, pp. 397-406
-
XIII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2020 (II)
Revista de neurologia, Vol. 72, Núm. 12, pp. 433-442
2020
-
Epidemiology of multiple sclerosis in Santiago de Compostela (Spain)
Acta Neurologica Scandinavica, Vol. 142, Núm. 3, pp. 267-274